Literature DB >> 18540961

B-cell-activating factor inhibits CD20-mediated and B-cell receptor-mediated apoptosis in human B cells.

Yohei Saito1, Yoshitaka Miyagawa, Keiko Onda, Hideki Nakajima, Ban Sato, Yasuomi Horiuchi, Hajime Okita, Yohko U Katagiri, Masahiro Saito, Toshiaki Shimizu, Junichiro Fujimoto, Nobutaka Kiyokawa.   

Abstract

B-cell-activating factor (BAFF) is a survival and maturation factor for B cells belonging to the tumour necrosis factor superfamily. Among three identified functional receptors, the BAFF receptor (BAFF-R) is thought to be responsible for the effect of BAFF on B cells though details of how remain unclear. We determined that a hairy-cell leukaemia line, MLMA, expressed a relatively high level of BAFF-R and was susceptible to apoptosis mediated by either CD20 or B-cell antigen receptor (BCR). Using MLMA cells as an in vitro model of mature B cells, we found that treatment with BAFF could inhibit apoptosis mediated by both CD20 and BCR. We also observed, using immunoblot analysis and microarray analysis, that BAFF treatment induced activation of nuclear factor-kappaB2 following elevation of the expression level of Bcl-2, which may be involved in the molecular mechanism of BAFF-mediated inhibition of apoptosis. Interestingly, BAFF treatment was also found to induce the expression of a series of genes, such as that for CD40, related to cell survival, suggesting the involvement of a multiple mechanism in the BAFF-mediated anti-apoptotic effect. MLMA cells should provide a model for investigating the molecular basis of the effect of BAFF on B cells in vitro and will help to elucidate how B cells survive in the immune system in which BAFF-mediated signalling is involved.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18540961      PMCID: PMC2612553          DOI: 10.1111/j.1365-2567.2008.02872.x

Source DB:  PubMed          Journal:  Immunology        ISSN: 0019-2805            Impact factor:   7.397


  53 in total

1.  TACI and BCMA are receptors for a TNF homologue implicated in B-cell autoimmune disease.

Authors:  J A Gross; J Johnston; S Mudri; R Enselman; S R Dillon; K Madden; W Xu; J Parrish-Novak; D Foster; C Lofton-Day; M Moore; A Littau; A Grossman; H Haugen; K Foley; H Blumberg; K Harrison; W Kindsvogel; C H Clegg
Journal:  Nature       Date:  2000-04-27       Impact factor: 49.962

2.  TALL-1 is a novel member of the TNF family that is down-regulated by mitogens.

Authors:  H B Shu; W H Hu; H Johnson
Journal:  J Leukoc Biol       Date:  1999-05       Impact factor: 4.962

3.  Apoptosis of malignant human B cells by ligation of CD20 with monoclonal antibodies.

Authors:  D Shan; J A Ledbetter; O W Press
Journal:  Blood       Date:  1998-03-01       Impact factor: 22.113

4.  Identification and characterization of a novel cytokine, THANK, a TNF homologue that activates apoptosis, nuclear factor-kappaB, and c-Jun NH2-terminal kinase.

Authors:  A Mukhopadhyay; J Ni; Y Zhai; G L Yu; B B Aggarwal
Journal:  J Biol Chem       Date:  1999-06-04       Impact factor: 5.157

5.  Interaction of the TNF homologues BLyS and APRIL with the TNF receptor homologues BCMA and TACI.

Authors:  S A Marsters; M Yan; R M Pitti; P E Haas; V M Dixit; A Ashkenazi
Journal:  Curr Biol       Date:  2000-06-29       Impact factor: 10.834

6.  Severe B cell hyperplasia and autoimmune disease in TALL-1 transgenic mice.

Authors:  S D Khare; I Sarosi; X Z Xia; S McCabe; K Miner; I Solovyev; N Hawkins; M Kelley; D Chang; G Van; L Ross; J Delaney; L Wang; D Lacey; W J Boyle; H Hsu
Journal:  Proc Natl Acad Sci U S A       Date:  2000-03-28       Impact factor: 11.205

7.  BAFF binds to the tumor necrosis factor receptor-like molecule B cell maturation antigen and is important for maintaining the peripheral B cell population.

Authors:  J S Thompson; P Schneider; S L Kalled; L Wang; E A Lefevre; T G Cachero; F MacKay; S A Bixler; M Zafari; Z Y Liu; S A Woodcock; F Qian; M Batten; C Madry; Y Richard; C D Benjamin; J L Browning; A Tsapis; J Tschopp; C Ambrose
Journal:  J Exp Med       Date:  2000-07-03       Impact factor: 14.307

8.  TACI is a TRAF-interacting receptor for TALL-1, a tumor necrosis factor family member involved in B cell regulation.

Authors:  X Z Xia; J Treanor; G Senaldi; S D Khare; T Boone; M Kelley; L E Theill; A Colombero; I Solovyev; F Lee; S McCabe; R Elliott; K Miner; N Hawkins; J Guo; M Stolina; G Yu; J Wang; J Delaney; S Y Meng; W J Boyle; H Hsu
Journal:  J Exp Med       Date:  2000-07-03       Impact factor: 14.307

9.  Mice transgenic for BAFF develop lymphocytic disorders along with autoimmune manifestations.

Authors:  F Mackay; S A Woodcock; P Lawton; C Ambrose; M Baetscher; P Schneider; J Tschopp; J L Browning
Journal:  J Exp Med       Date:  1999-12-06       Impact factor: 14.307

10.  BAFF, a novel ligand of the tumor necrosis factor family, stimulates B cell growth.

Authors:  P Schneider; F MacKay; V Steiner; K Hofmann; J L Bodmer; N Holler; C Ambrose; P Lawton; S Bixler; H Acha-Orbea; D Valmori; P Romero; C Werner-Favre; R H Zubler; J L Browning; J Tschopp
Journal:  J Exp Med       Date:  1999-06-07       Impact factor: 14.307

View more
  11 in total

Review 1.  Recent Advances in Monoclonal Antibody Therapies for Multiple Sclerosis.

Authors:  Bharath Wootla; Jens O Watzlawik; Nikolaos Stavropoulos; Nathan J Wittenberg; Harika Dasari; Murtada A Abdelrahim; John R Henley; Sang-Hyun Oh; Arthur E Warrington; Moses Rodriguez
Journal:  Expert Opin Biol Ther       Date:  2016-03-10       Impact factor: 4.388

2.  Differential effects of BAFF on B cell precursor acute lymphoblastic leukemia and Burkitt lymphoma.

Authors:  Keiko Onda; Kazutoshi Iijima; Yohko U Katagiri; Hajime Okita; Masahiro Saito; Toshiaki Shimizu; Nobutaka Kiyokawa
Journal:  Int J Hematol       Date:  2010-04-29       Impact factor: 2.490

3.  B Cell-Activating Factor. An Orchestrator of Lymphoid Follicles in Severe Chronic Obstructive Pulmonary Disease.

Authors:  Francesca Polverino; Borja G Cosio; Jaime Pons; Maria Laucho-Contreras; Paula Tejera; Amanda Iglesias; Angel Rios; Andreas Jahn; Jaume Sauleda; Miguel Divo; Victor Pinto-Plata; Lynette Sholl; Ivan O Rosas; Alvar Agustí; Bartolome R Celli; Caroline A Owen
Journal:  Am J Respir Crit Care Med       Date:  2015-09-15       Impact factor: 21.405

4.  Antibodies against CD20 or B-cell receptor induce similar transcription patterns in human lymphoma cell lines.

Authors:  Andreas Franke; Gerhard J Niederfellner; Christian Klein; Helmut Burtscher
Journal:  PLoS One       Date:  2011-02-18       Impact factor: 3.240

5.  Integrin-specific hydrogels as adaptable tumor organoids for malignant B and T cells.

Authors:  Ye F Tian; Haelee Ahn; Rebecca S Schneider; Shao Ning Yang; Lidia Roman-Gonzalez; Ari M Melnick; Leandro Cerchietti; Ankur Singh
Journal:  Biomaterials       Date:  2015-09-11       Impact factor: 12.479

6.  Endotoxemia contributes to CD27+ memory B-cell apoptosis via enhanced sensitivity to Fas ligation in patients with Cirrhosis.

Authors:  Li-Yuan Chang; Yonghai Li; David E Kaplan
Journal:  Sci Rep       Date:  2016-11-18       Impact factor: 4.379

Review 7.  Recent advances in the immunological understanding of association between tonsil and immunoglobulin A nephropathy as a tonsil-induced autoimmune/inflammatory syndrome.

Authors:  Yasuaki Harabuchi; Miki Takahara
Journal:  Immun Inflamm Dis       Date:  2019-04-07

8.  B Cell-Activating Factor Promotes B Cell Survival in Ectopic Lymphoid Tissues in Nasal Polyps.

Authors:  Zhe-Zheng Wang; Jia Song; Hai Wang; Jing-Xian Li; Qiao Xiao; Ze Yu; Jin-Xin Liu; Zheng Liu
Journal:  Front Immunol       Date:  2021-01-20       Impact factor: 7.561

9.  Deletion of Snai2 and Snai3 results in impaired physical development compounded by lymphocyte deficiency.

Authors:  Peter D Pioli; Timothy J Dahlem; Janis J Weis; John H Weis
Journal:  PLoS One       Date:  2013-07-16       Impact factor: 3.240

10.  Characterization of a case of follicular lymphoma transformed into B-lymphoblastic leukemia.

Authors:  Yi Ning; Aubry Foss; Amy S Kimball; Nicholas Neill; Tricia Matz; Roger Schultz
Journal:  Mol Cytogenet       Date:  2013-08-28       Impact factor: 2.009

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.